February 25, 2020 / 10:23 AM / a month ago

Novartis launched review into safety of eye drug Beovu

ZURICH, Feb 25 (Reuters) - Novartis has launched an external review into the safety of its blindness medicine Beovu after the American Society of Retinal Specialists (ASRS) raised concerns.

The Swiss drugmaker’s shares fell nearly 3% in early trading after the ASRS communicated to its members about the drug, a replacement for Novartis’s blockbuster Lucentis.

Reporting by John Revill; editing by Jason Neely

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below